The award will fund development of a rapid, sensitive, and specific diagnostic system for the culture-independent identification and determination of antimicrobial susceptibility of bacterial pathogens from whole blood.
Talis is developing a high-performance diagnostic platform to enable physician offices and clinics to run reference lab quality diagnostic tests for infectious diseases at the point-of-care.
Point-of-care diagnostic platforms that can measure the drug susceptibility of a pathogen directly from clinical samples, eliminating lengthy procedures that require microbial growth can help in the fight against antibiotic resistant organisms.
The Talis system leverages proprietary isothermal amplification chemistries, innovative engineering and data science tools. The rapid, digital quantification capability of the company's proprietary SlipChip technology of parallel processing of thousands of nanoliter volume chambers will enable pathogen identification and susceptibility to antibiotics in less than two hours.
Talis is developing a new class of diagnostic systems to enable rapid, point of care testing across a wide range of healthcare settings. From the doctor's office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial